ABSTRACT
The principle of complementarity refers to the ability of quantum entities to behave as particles or waves under different experimental conditions. We present a proposal for the experimental observation of the ultrafast all-optical control of the wave-particle duality of light. The device is constituted by a three-level quantum emitter strongly coupled to a microcavity (MC) and can be realized by exploiting a great variety of systems, ranging from atomic physics and semiconductor quantum dots to intersubband polaritons and Cooper pair boxes. The wavelike or particlelike behavior of MC photons can be probed by simply measuring the cavity output photon rate after excitation with pairs of phase-locked weak pulses with precise arrival times.
ABSTRACT
We study the all-optical time control of the strong coupling between a single cascade three-level quantum emitter and a microcavity. We find that only specific arrival times of the control pulses succeed in switching off the Rabi oscillations. Depending on the arrival times of control pulses, a variety of exotic nonadiabatic cavity quantum electrodynamics effects can be observed. We show that control pulses with specific arrival times, performing which-path and quantum-eraser operations, are able to suddenly switch-off and on first-order coherence of cavity photons, without affecting their strong coupling population dynamics.
ABSTRACT
Positron emission tomography (PET) is a powerful non-invasive probe to investigate human physiology. A large number of radiotracers have been studied as imaging agents, but only a few have found clinical applications in pharmacology. A potential radiopharmaceutical is designed with very specific physiochemical characteristics, but, generally, less attention is paid to its adsorption, distribution, metabolism, and excretion properties, especially metabolism. Understanding the metabolic fate of radiopharmaceutical probes is essential for an accurate analysis and interpretation of PET measurements. The inherent inability of PET to differentiate between a parent compound and its metabolites confounds the interpretation of images and may impact the identification of the pathologically induced biochemical changes under investigation. Cytochrome P450 plays a major role in mammalian xenobiotic biotransformation and many in vitro methods are available to study and predict drug metabolism. The purpose of this review is to highlight the existing in vitro techniques available to investigate the biotransformation of xenobiotics in a fashion analogous to small molecule drug discovery. The aim is to facilitate the development and validation phases of PET tracers during preclinical evaluation. Emphasis is placed also on describing how cross species comparisons are essential in establishing appropriate translational pharmacology. Procedures of analysis (tandem liquid chromatography-mass spectrometry), typically used for studying the metabolism of drugs, are proposed as quick and accurate tools for the determination of a radiopharmaceutical's metabolic stability at the tracer level.
